Micro Labs USA launches 2 generics
Micro Labs USA is introducing two new generic products, which are used for treating Glaucoma, a condition characterized by increased intraocular pressure.
The first new product is dorzolamide ophthalmic solution. It is available in a dosage strength of 2%. The company also is launching dorzolamide and timolol ophthalmic solution in a dosage strength of 22.3-6.8 mg/mL.
The company is vertically integrated in the drug substance dorzolamide and its manufacturing capacities are "doubling to address the growing need for these two ophthalmic products."
Dorzolamide, and dorzolamide and timolol have a market value of approximately $150 million, according to IQVIA.